|1.||Wainer, Irving W: 4 articles (07/2014 - 07/2010)|
|2.||Torjman, Marc C: 3 articles (07/2014 - 07/2010)|
|3.||Mager, Donald E: 3 articles (08/2012 - 07/2010)|
|4.||Dahan, Albert: 3 articles (08/2012 - 10/2009)|
|5.||Moaddel, Ruin: 2 articles (07/2014 - 08/2012)|
|6.||Niesters, Marieke: 2 articles (08/2012 - 07/2011)|
|7.||Aarts, Leon: 2 articles (08/2012 - 07/2011)|
|8.||Sarton, Elise: 2 articles (08/2012 - 10/2009)|
|9.||Olofsen, Erik: 2 articles (08/2012 - 10/2009)|
|10.||Goldberg, Michael E: 2 articles (02/2011 - 07/2010)|
|1.||Multiple Organ Failure (MODS)
10/01/2008 - "Effects of norketamine enantiomers in rodent models of persistent pain."
02/01/2011 - "This study determined the pharmacokinetics and pharmacodynamics of (R)- and (S)-ketamine and (R)- and (S)-norketamine following a 5-day moderate dose, as a continuous (R,S)-ketamine infusion in complex regional pain syndrome (CRPS) patients. "
04/01/2015 - "Given that the analgesic effect of S-ketamine is due to both S-ketamine and norketamine, relatively small oral doses of S-ketamine can be assumed to be a feasible alternative to repeated intravenous dosing, for example in the setting of chronic pain."
08/01/2012 - "Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers."
07/01/2010 - "The pain relief experienced on Day 2 of the infusion continued to improve over the 5-day infusion period and correlated with the maximum plasma levels of ketamine and norketamine. "
|3.||Peripheral Nervous System Diseases (PNS Diseases)
10/01/2008 - "S(+) and R(-)norketamine were characterized utilizing rodent models of persistent pain: the chronic constriction nerve injury model of peripheral neuropathy (CCI) and the formalin-injection model of tonic inflammatory pain (formalin test). "
10/01/2008 - "In the present study, morphine (a low dose) was combined with S(+)- and R(-)-norketamine (sub-antinociceptive doses) and characterized utilizing rodent models of pain including: thermal nociception (the tail-flick test), peripheral neuropathy (chronic constriction nerve injury) and tonic inflammatory pain (the formalin test). "
|4.||Neuralgia (Stump Neuralgia)
07/01/2011 - "Ketamine, its active metabolite norketamine, and the NR2B-selective antagonist traxoprodil (CP-101,606) were tested in rat models of acute antinociception (paw-withdrawal response to heat) and chronic neuropathic pain (spared nerve injury). "
01/01/1995 - "Response of chronic neuropathic pain syndromes to ketamine: a role for norketamine?"
10/01/2008 - "Norketamine alleviated, in a dose-dependent fashion, mechanical and thermal hyperalgesia (CCI), and blocked formalin-induced flinches (2nd phase). "
10/01/2008 - "The data showed that: 1) Norketamine enhanced morphine antinociception and blocked tolerance to this effect; 2) Norketamine potentiated morphine effectiveness in the alleviation of symptoms resulting from injury to nerve (mechanical hyperalgesia, tactile allodynia) and peripheral tissue (formalin-induced nociceptive behavior); 3) S(+)-norketamine was more potent than R(-)-norketamine; 4) Antinociception was not confounded by significant side effects. "
|4.||Morphine (MS Contin)
|2.||Intensive Care (Surgical Intensive Care)
|3.||Combination Drug Therapy (Combination Chemotherapy)